Kenneth Bender, PharmD, MA

Updated review and meta-analysis identifies the classes of antibiotics most strongly linked to healthcare facility-associated Clostridioides difficile infection.

Laboratory escape is described as an extremely unlikely source for SARS-CoV-2 in new WHO report, but questions posed to the researchers remain open.

Higher hitamin D levels could be needed in Black persons than in White persons to support immune system and reduce risk of COVID-19.

Serum neutralizing antibodies to SARS-CoV-2 from infection or vaccination were found to recognize and act against new variants of the virus.

Recruitment for a phase 2 trial of a novel antibiotic against Clostridium difficile (C diff) is proceeding after phase 1 demonstrated safety and tolerability.

Strong immunologic responses to vaccination for SARS-CoV-2 in COVID-19 survivors suggest that first of 2-dose vaccination could suffice.

One month after the Food and Drug Administration (FDA) approval of monthly rilpivirine/cabotegravir (Cabenuva) for HIV, Janssen has submitted evidence of efficacy with dosing every 2 months.

A review of approximately 1000 children with multisystem inflammatory syndrome (MIS-C) from SARS-Cov-2 finds low fatality with aggressive treatment.

An investigational HCV vaccine induced immunologic response and was well tolerated, but did not protect against infection.

HIV-associated wasting remains common complication despite treatment with antiretroviral therapy.

An orally administered adsorbent to prevent antibiotic disruption of intestinal flora enters phase 3 trial against clostridium difficile (C diff) in patients with hematologic malignancies.

A protein subunit vaccine candidate for COVID-19 demonstrated safety and immunogenicity in a phase 1, placebo-controlled, dose escalation trial.

In the most recent trials of tocilizumab for COVID-19, patients with moderate illness benefited but survival rate of severely ill did not improve or worsened.

Presence of GI symptoms with COVID-19 was associated with increased likelihood of severe illness.

“Federated learning,” a new machine learning technique, could improve prediction of COVID-19 outcomes and enhance patient triage and care.

Interest and evidence for "repurposing" antiparasitic invermectin for COVID-19 is increasing.

Allergists offer risk stratification approach to avoid rare allergic reaction to COVID-19 vaccines

The ADVANCE study results at 96 weeks distinguish between the long-term effects of 3 combination regimens for HIV in weight gain and bone density change.

Participants in clinical trials of long-acting injectable antiretroviral therapy for HIV describe expectations and experience with the investigational dosage form.

An investigational microbiome-based therapeutic for C difficile was found to exert continued efficacy 3 months after administration.

Antiviral therapy that suppresses HIV-1 viremia does not block release of cell-associated RNA after infection or the inflammatory response it provokes.

Patients testing positive for SARS-CoV-2 after recovery and negative tests are re-examined to determine if they are reinfected and/or infectious.

The final report of remdesivir trial supports its approved treatment for COVID-19 after preliminary findings enabled emergency use authorization.

An investigational vaccine for C difficile demonstrates multiyear efficacy in trials reported at 2020 IDWeek Conference.

Phase 2 trial demonstrates novel investigational antifungal Fosmanogepix is tolerated and efficacious in patients with renal Insufficiency.

Virologists have identified a gene encoded by SARS-CoV-2 that enables it, but not SARS-CoV or Influenza A viruses, to inhibit interferon-based immune response

Invasive C glabrata found to be most prevalent strain of Candida in stool of patients with C difficile infection, and likely resistant to caspofungin.

An antiprotozoal used in veterinary medicine demonstrates potential for repurposing to replace metronidazole to treat Clostridioides difficile.

Influenza vaccination during COVID-19 could keep health resources from being overwhelmed and mitigate cardiovascular risks.

National Academies committee releases discussion draft on equitable allocation of vaccine against novel coronavirus for public comment.